Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
Background: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40...
Main Authors: | Michala Skovlund Sørensen, Thomas Colding-Rasmussen, Peter Frederik Horstmann, Klaus Hindsø, Christian Dehlendorff, Julia Sidenius Johansen, Michael Mørk Petersen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2833 |
Similar Items
-
The role of YKL-40 in a cancerous process
by: Agnieszka Rusak, et al.
Published: (2016-12-01) -
Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
by: Camilla Bjørnbak Holst, et al.
Published: (2020-04-01) -
Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease
by: Xue Xu, et al.
Published: (2014-08-01) -
A Comparative Study Of Lamps And Ykl-40 Tissue Expression In Glial Tumors
by: Kazakova Maria Hr., et al.
Published: (2014-09-01) -
The Relationship between Serum YKL-40 Levels and Severity of Asthma
by: Serap Duru, et al.
Published: (2013-09-01)